Systematic analysis of the necroptosis index in pan-cancer and classification in discriminating the prognosis and immunotherapy responses of 1716 glioma patients

• Main Authors: Shuai Ma (Author), Fang Wang (Author), Qingzhen Liu (Author), Xiaoteng Geng (Author), Zaibin Wang (Author), Menglei Yi (Author), Fan Jiang (Author), Dongtao Zhang (Author), Junzheng Cao (Author), Xiuwei Yan (Author), Jiheng Zhang (Author), Nan Wang (Author), Heng Zhang (Author), Lulu Peng (Author), Zhan Liu (Author), Shaoshan Hu (Author), Shengzhong Tao (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1663-9812; 10.3389/fphar.2023.1170240
• Keywords: necroptosis index; pancacer; glioma; chemoradiotherapy; immunotherapy; Therapeutics. Pharmacology; RM1-950
• Source: Frontiers in Pharmacology, Vol 14 (2023)

Necroptosis is a programmed form of necrotic cell death that serves as a host gatekeeper for defense against invasion by certain pathogens. Previous studies have uncovered the essential role of necroptosis in tumor progression and implied the potential for novel therapies targeting necroptosis. However, no comprehensive analysis of multi-omics data has been conducted to better understand the relationship between necroptosis and tumor. We developed the necroptosis index (NI) to uncover the effect of necroptosis in most cancers. NI not only correlated with clinical characteristics of multiple tumors, but also could influence drug sensitivity in glioma. Based on necroptosis-related differentially expressed genes, the consensus clustering was used to classify glioma patients into two NI subgroups. Then, we revealed NI subgroup I were more sensitive to immunotherapy, particularly anti-PD1 therapy. This new NI-based classification may have prospective predictive factors for prognosis and guide physicians in prioritizing immunotherapy for potential responders.